Trial Profile

A Phase 1 double-blind, placebo-controlled, first-in-human, single-ascending dose trial of APG808 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APG 808 (Primary)
Indications Chronic obstructive pulmonary disease
Focus Adverse reactions; First in man

Most Recent Events

02 Dec 2024 Interim Results presented in the Apogee Therapeutics Media Release.
12 Nov 2024 According to an Apogee Therapeutics media release, the company expects to report interim Phase 1 data for APG808 in the fourth quarter of 2024.
25 Mar 2024 Status changed from planning to recruiting, According to Apogee Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com